

June 7, 2019

Meta Biomed Co., Ltd. % April Lee Consultant Withus Group Inc 106 Superior Irvine, California 92620

Re: K190503

Trade/Device Name: CeraSeal

Regulation Number: 21 CFR 872.3820 Regulation Name: Root Canal Filling Resin

Regulatory Class: Class II

Product Code: KIF Dated: March 11, 2019 Received: March 19, 2019

Dear April Lee:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

K190503 - April Lee Page 2

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Srinivas Nandkumar, Ph.D.
Assistant Director
DHT1B: Division of Dental Devices
OHT1: Office of Ophthalmic, Anesthesia,
Respiratory, ENT and Dental Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2020 See PRA Statement below.

510(k) Number (if known)	
K190503	
Device Name	
CeraSeal	
Indications for Use (Describe)	
• Permanent obturation of the root canal following vital pulp-	extirpation
• Permanent obturation of the root canal following removal of	f infected or necrotic pulp and placement of intracanal
dressings	
CeraSeal is suitable for use in the single cone and lateral conde	ensation technique.
	1
Type of Use (Select one or both, as applicable)	
	Over-The-Counter Use (21 CFR 801 Subpart C)
M Flescription Ose (Part 21 GFR 601 Suppart D)	
CONTINUE ON A SEPARA	ATE PAGE IE NEEDED
CONTINUE ON A SEPAR	ATE LAGE IL MEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



Address 270, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Korea Tel +82-43-216-0433 Fax +82-43-217-1988 METABIOMED CO.LTD.
E-mail
info@meta-biomed.com
http://www.meta-biomed.com

510(k) Summary K190503

Submitter

META BIOMED CO., LTD.

Suk Song Oh

270, Osongsaengmyeong 1-ro, Osong-eup,

Heungdeok-gu, Cheongju-si, Chungcheongbuk-do,

South Korea

Email: ef1459@metabiogw.bizmeka.com

Phone: +82-43-230-8841 Fax: +82-43-217-1983

Device Information

• Trade Name: CeraSeal

• Classification Name: resin, root canal filling

Product Code: KIFPanel: Dental

• Regulation Number: 21 CFR 872.3820

Device Class: Class IIDate prepared: 02/20/2019

Predicate Devices:

• K080917, iRoot SP manufactured by Innovative BioCeramix Inc.

Device Description

CeraSeal is used for root canal filling after the removal of infected pulp tissue in the root canal. CeraSeal is in the form of a flowable paste and can be immediately applied inside the root canal using a disposable tip. material, and a thickening agent. This product characteristically cures slowly by absorbing the ambient water inside the root canal. It is white and aesthetic.

Indication for Use

- Permanent obturation of the root canal following vital pulp-extirpation
- Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings

CeraSeal is suitable for use in the single cone and lateral condensation technique.

Official Correspondent

Withus Group Inc

106 Superior,

USA

April Lee

Email: withus 6664@gmail.com

Phone: 1-909-274-9971 Fax: 1-909-460-8122



Address 270, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Korea

+82-43-216-0433 Fax +82-43-217-1988 METABIOMED CO.LTD.
E-mail
info@meta-biomed.com
http://www.meta-biomed.com

Non-clinical Testing

The following testing was conducted on our subject device:

- Biocompatibility Tests according to ISO 10993-1:2009, ISO 10993-5:2009, ISO 10993-10:2010, ISO 10993-11:2006.
- Performance tests such as visual, capacity, package, flow, setting time, film thickness, solubility and radio-opacity according to ISO 6876:2012.
- Shelf Life test: ISO 6876 tests (extraneous matter, package, flow, setting time, film thickness and Solubility)

Summary of Technological Characteristics:

The subject device and the predicate device have the same intended use and have the similar technological characteristics and are made of similar materials. They encompass the same range of physical and chemical properties. The subject device and predicate devices are packaged in similar material and use similar methods of application.

The subject device is different from the predicate devices in raw materials, however, the test results provided in this submission supports that it is substantially equivalent to the predicate device.

	Subject Device	Predicate Device
Manufacturer	Meta Biomed Co., Ltd.	Innovative BioCeramix, Inc.
Device Name	CeraSeal	iRoot SP
510(k) Number	NA	K080917
Classification Name	resin, root canal filling	resin, root canal filling
Product Code	KIF	KIF
Regulation Number	21 CFR 872.3820	21 CFR 872.3820
Indications for use	 Permanent obturation of the root canal following vital pulp-extirpation Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings CeraSeal is suitable for use in the single cone and lateral condensation technique. 	 Permanent obturation of the root canal following vital pulp-extirpation Permanent obturation of the root canal following removal of infected or necrotic pulp and placement of intracanal dressings iRoot SP is suitable for use in the single cone and lateral condensation technique.



Address 270, Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Korea

+82-43-216-0433 Fax +82-43-217-1988 METABIOMED CO.LTD. E-mail info@meta-biomed.com http://www.meta-biomed.com

	Insoluble, radiopaque material based on a calcium silicate compound containing:	Insoluble, radiopaque material based on a calcium silicate compound containing:
Raw Material	Thickening agent	Thickening agent
	Zirconium dioxide	Zirconium oxide filler
	Calcium silicates	Calcium silicates
	1, 3 Propanediol	Calcium phosphate monobasic Calcium hydroxide
Principle of Operation	identical	iRoot SP is a convenient premixed ready- to-use injectable white hydraulic cement paste developed for permanent root canal filling and sealing applications. iRoot SP is an insoluble, radiopaque material which requires the presence of water to set and harden. iRoot SP is packaged in a pre-loaded syringe and is supplied with disposable tips.
Performance Standard Conformance	Conformed to ISO 6876	Conformed to ISO 6876
Biocompatibility	Yes	Yes
Use	Prescription / Hospital	Prescription / Hospital
Delivery Forms	Single Paste	Single Paste
Sterility	Non-sterile	Non-sterile
Shelf Life	2 years	2 years
	•	•

Conclusion:

Based on documentation supplied with this submission, conclusions drawn from the testing results demonstrate that the subject device is substantially equivalent to our legally marketed predicate device.